Navigation Links
Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
Date:8/22/2007

- Revised Trial Examines Single, Higher, More Concentrated Dose of

Alfimeprase -

SAN CARLOS, Calif., Aug. 22 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO) today announced enrollment of the first patient in the SONOMA-3 (Speedy Opening of Non-functional and Occluded catheters with Mini-dose Alfimeprase-3) trial evaluating lead product candidate, alfimeprase, for the treatment of central venous catheter occlusion (CO).

This open-label, single-arm trial will evaluate the safety and efficacy of a single 10 milligram dose of alfimeprase with a concentration of 5 milligrams per milliliter in up to 100 patients with occluded central venous catheters.

Data from a previous Phase 3 trial in the CO program, SONOMA-2, showed that alfimeprase restored catheter function in patients with occluded catheters within 15 minutes with a p-value of 0.022. It did not however, meet the more stringent p-value required for a single pivotal trial, less than 0.00125.

"Analysis of data from our previous Phase 3 SONOMA study provided further evidence that alfimeprase is an active thrombolytic which has the potential to dissolve clots quickly and rapidly restore catheter function, however, the dose and concentration we used did not generate results in line with the target product profile we believe necessary for commercial success in this market," said Michael Levy, M.D., executive vice president of research and development for Nuvelo. "Preclinical experiments have provided evidence that increasing the concentration can result in marked improvement in thrombolytic activity. Accordingly, we are resuming development of alfimeprase in CO to evaluate the potential of a single, higher, m
'/>"/>

SOURCE Nuvelo, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
3. Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas
4. Nuvelo Announces Publication of NU206 Study Results in Gastroenterology
5. Nuvelo Announces Presentation on NU206 at 2007 American Association for Cancer Research Annual Meeting
6. Nuvelo Announces Presentation on rNAPc2 at American College of Cardiology 56th Annual Scientific Session
7. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... N.C., Oct. 20, 2014  BioPontis Alliance for ... both philanthropies, announced today the creation of a ... treatment of the rare disease known as Charcot- ... its alliance model earlier this month. Today,s partnership ... a collaborative model where researchers and all CMT ...
(Date:10/19/2014)... 19, 2014  Henry Schein, Inc. (NASDAQ: ... products and services to office-based dental, animal health and ... Iwase Dental Supply, Inc., a leading full-service provider of ... Henry Schein,s entrance into Japan , ... increases to 28 the number of countries in which ...
(Date:10/17/2014)... 17, 2014 With the recent changes ... has come across several challenges in creating and ... globalization.  The Medical Affairs ... to providing benchmarking and best practices across critical ... a service composed of three stages: 1) member-driven ...
Breaking Medicine Technology:The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 2The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 3Henry Schein Enters Japan With Investment in Iwase Dental Supply 2Henry Schein Enters Japan With Investment in Iwase Dental Supply 3Henry Schein Enters Japan With Investment in Iwase Dental Supply 4Henry Schein Enters Japan With Investment in Iwase Dental Supply 5Early Key Findings from the Medical Affairs Consortium Research 2
... /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: ... R&D outsourcing company with operations in China and the ... results for the third quarter of 2011 after the ... 2011 (which will be Friday morning, November 11, 2011 ...
... CLOSTER, N.J., Oct. 25, 2011 Ericom Software, ... virtualization solutions, today announced the availability of Ericom ... the AccessNow HTML5 product family. AccessNow for Enterprise ... desktops within leading enterprise portals, including IBM WebSphere ...
Cached Medicine Technology:WuXi PharmaTech Schedules Third-Quarter 2011 Earnings Release 2Ericom AccessNow™ for Enterprise Portals - Secure, Portal-based, HTML5 Web Access to Windows Applications, Desktops and Services 2Ericom AccessNow™ for Enterprise Portals - Secure, Portal-based, HTML5 Web Access to Windows Applications, Desktops and Services 3
(Date:10/20/2014)... My Clients Plus ( http://www.MyClientsPlus.com ) today ... new module enables easy administration and routing of follow-up ... , This application allows users such as Therapists to ... to-do item to a specific client, categorize tasks the ... reminders for follow-ups. It's designed to enable easy ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 ... Voicheck as Assistant Director of their CentralSource ... in managing the innovative turnkey drug sourcing, distribution, ... Matthew brings over 12 years of industry experience, ... Myoderm at the peak of their international success ...
(Date:10/20/2014)... Based on a proprietary chromatid-specific ... assays capable of determining DNA sequence, location and ... three dimensions of high-resolution data, dGH assays are ... range of disease-causing genetic rearrangements, including chromosomal inversions ... tools, including today’s advanced sequencing technologies. , According ...
(Date:10/20/2014)... Ohio (PRWEB) October 20, 2014 Unveiled at ... new Strategic Direction Scorecard conservatively estimates member hospital ROI on ... spent on dues, The Center provides $12.50 in value to ... is (Member Value – Member Dues)/Member Dues. , “This ... at this number and we think the methodology is really ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Houston plastic ... present the key elements of his innovative True ... to plastic surgery residents and faculty at The ... where he, too, was once a medical student. Patronella, ... largest private cosmetic plastic surgery practices in Texas, ...
Breaking Medicine News(10 mins):Health News:My Clients Plus Announces New Workflow Management Software 2Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2
... of actual resveratrol plus 95% OPCs ... and three ... manufacturer,Renaissance Health Publishing, LLC, is disappointed and confused as to ... of Revatrol, and calls on the for-profit laboratory,to remove the ...
... often be the smarter choice, study suggests , MONDAY, Nov. ... symptoms of throat infection, surgery to remove the tonsils is ... watching and waiting to see if symptoms resolve, a Dutch ... University Medical Center Utrecht compared 151 children, ages 2 to ...
... McCandliss, a psychologist at the Sackler Institute for Developmental ... Weill Cornell Medical College, has received a commendation by ... of a Presidential Early Career Award for Scientists and ... by the U.S. government for outstanding scientists and engineers ...
... new article appearing in American Journal of Transplantation describes ... of organ rejection in kidney transplants. The technique, which ... examining DNA sequences, defines how major causes of organ ... behavior. The study is the first to show how ...
... Booker, II, CPA, Presented with Charles Kopke,Medal ... Nov. 19 The American,Diabetes Association (ADA), ... fight against diabetes, announced today that G. ... Arkansas, received the,Association,s prestigious Charles Kopke Medal ...
... an,important step toward protecting patient access to essential ... Fracture Prevention and,Osteoporosis Testing Act of 2007," sponsored ... a reversal of drastic Medicare cuts,to DXA (dual ... the gold standard for measuring bone mass to ...
Cached Medicine News:Health News:ConsumerLab.com Study On Revatrol NOT Based on Current Formulation - the Revatrol Sample Used Was More Than Nine Months Out-Of-Date, says Renaissance Health Publishing 2Health News:ConsumerLab.com Study On Revatrol NOT Based on Current Formulation - the Revatrol Sample Used Was More Than Nine Months Out-Of-Date, says Renaissance Health Publishing 3Health News:Tonsillectomy Not Always Cost-Effective for Kids' Throat Woes 2Health News:White House awards Weill Cornell's Bruce McCandliss highest honor for early career scientists 2Health News:Breakthrough in organ rejection diagnosis examines gene behavior 2Health News:Bill Booker Receives American Diabetes Association's Distinguished Service Award 2Health News:Bill Booker Receives American Diabetes Association's Distinguished Service Award 3Health News:Congress Moves to Protect Bone Health 2
Allows for custom orientation of specimen...
Honing compound for knife sharpening, 6 grams net...
Standard knife with box, C profile...
... sectioning work, it is necessary to cool a ... can be fitted to most microtomes and will ... lower, depending on conditions. The equipment consists of ... cooling stage is best suited for operation with ...
Medicine Products: